Document:

Common Stock Warrant, dated July 10, 2003

 Exhibit 4.1 
  
 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED OR ANY APPLICABLE STATE SECURITIES LAWS AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH
A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
AS TO THIS WARRANT OR THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT, RESPECTIVELY, UNDER SAID ACT OR QUALIFICATION RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION OR QUALIFICATION IS NOT
REQUIRED. 
  
 CV THERAPEUTICS, INC. 
  
 WARRANT TO PURCHASE SHARES OF COMMON STOCK 
  
 Issuance Date: July 9, 2003 
  
 THIS CERTIFIES THAT, for value received, QFinance, Inc., a Delaware
corporation (an affiliate of Quintiles Transnational Corp.) and its registered assigns (the “Holder”), is entitled to subscribe for and purchase 200,000 shares (as adjusted pursuant to the provisions hereof, the
“Shares”) of the common stock of CV Therapeutics, Inc., a Delaware corporation (the “Company”), at the Exercise Price (defined below), upon such terms and conditions as hereinafter set forth. 
  
 1. Exercise Period. This Warrant shall be exercisable, in whole or in
part, during the term commencing on the Issuance Date and ending at 5:00 p.m. Pacific Time on the fifth (5th)
anniversary of the Issuance Date. 
  
 2. Exercise Price.
The exercise price for the Shares shall be $32.93 per share (the “Exercise Price”). The Exercise Price is subject to adjustment from time to time as set forth below. 
  
 3. Method of Exercise; Net Issue Exercise. 
  
 (a) Method of Exercise; Payment; Issuance of New Warrant. This Warrant may be exercised by Holder, in whole or in
part, by the surrender of this Warrant (with the Notice of Exercise form attached hereto as Exhibit A-1 duly executed) at the principal office of the Company and by the payment to the Company, by cash, check or wire transfer in immediately available
funds, of an amount equal to the Exercise Price per share multiplied by the number of Shares then being purchased hereunder. The person or persons in whose name(s) any certificate(s) representing Shares shall be issuable upon exercise of this
Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the Shares represented thereby (and such Shares shall be deemed to have been issued) immediately prior to the close
of business on the date or dates upon which this Warrant is exercised. In the event of any exercise of this Warrant, certificates for the Shares so purchased shall be delivered to 
  

 Holder and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the
Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to Holder. 
  
 (b) Right to Convert Warrant into Stock; Net Issuance. In addition to and without limiting the rights of Holder under the terms of this Warrant and
in lieu of exercising this Warrant under Section 3(a) above, Holder may elect to convert this Warrant or any portion thereof (the “Conversion Right”), by surrender of this Warrant at the principal office of the Company (with the
Notice of Exercise form attached hereto as Exhibit A-1 duly executed), into that number of Shares computed using the following formula: 
  

	X = Y (A-B)
	      A

  

	 Where:
	  	 X =  The number of shares of common stock to be issued to Holder.

	 	  	 Y =  The number of shares of common stock covered by this Warrant in respect
of which the net issue election is made
          pursuant to this
Section 3(b).

	 	  	 A =  The fair market value of one share of the Company’s common stock.

	 	  	 B =   Exercise Price (as adjusted to the date of such calculations).

  
 (c) For purposes of
this Section, “fair market value” of one share of common stock shall mean the closing price as reported on the Nasdaq National Market or the principal exchange on which the common stock is listed, or, if the common stock is actively traded
over-the-counter, the closing bid or sale price (whichever is applicable) of the common stock on the trading day immediately preceding the date that the Exercise Notice is delivered to the Company. If the common stock is not listed or traded on any
market or exchange or over-the-counter, the fair market value of the common stock will be determined in good faith by the Board of Directors of the Company. 
  
 4. Stock Fully Paid; Reservation of Shares. All Shares to be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized,
validly issued, fully paid and nonassessable, and free from all liens and charges with respect to the issuance thereof. During the period within which this Warrant may be exercised, the Company will at all times have duly authorized and reserved,
for the purpose of issuance upon exercise of this Warrant, a sufficient number of shares of common stock. 
  
 5. Charges, Taxes and Expenses. Issuance of certificates for shares of common stock upon the exercise of this Warrant shall be made promptly and
without charge to Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the
registered holder of this Warrant; provided, however, that upon any transfer involved in the issuance or delivery of any certificates for shares of common stock, the Company may require, as a condition 
  

 -2- 

 thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. 
  
 6. Adjustments to Exercise Price and Number of Shares. The number and
kind of securities purchasable upon the exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time upon the occurrence of the following events: 
  
 (a) Reclassification; Consolidation or Merger. In case of any reclassification or reorganization of all of the
Company’s outstanding common stock (other than a change in par value, or as a result of a subdivision or combination), or in case of any consolidation or merger of the Company with or into another corporation, or comparable transaction (other
than a consolidation or merger with another corporation in which the Company is a continuing corporation and in which the Company’s stockholders immediately preceding such consolidation or merger own at least 50% of the voting securities of the
Company following such consolidation or merger and which does not result in any reclassification of the shares issuable upon exercise of this Warrant), or in the case of any sale, lease, license or other transfer of all or substantially all of the
assets of the Company, the Company, or such successor or purchasing corporation as the case may be, shall execute a new Warrant (or other provision shall be made), providing that Holder shall have the right to exercise such new Warrant, and procure
upon such exercise and payment of the same aggregate Exercise Price, in lieu of the shares of common stock theretofore issuable upon exercise of this Warrant, the kind and amount of shares of stock, other securities, money and property receivable
upon such reclassification, reorganization, change, consolidation, sale or transfer of all or substantially all of the Company’s assets or merger by a holder of an equivalent number of shares of common stock. Such new warrant shall provide for
adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 6. The provisions of this subsection (a) shall similarly apply to successive reclassifications, reorganization, consolidations,
mergers, and the sale or transfer of all or substantially all of the Company’s assets. 
  
 (b) Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine all of its outstanding common stock, the Exercise Price shall
be proportionately decreased (and the number of Shares proportionately increased to the nearest whole) in the case of a subdivision or increased (and the number of Shares proportionately decreased to the nearest whole) in the case of a combination.

  

 -3- 

 (c) Stock Dividends and other Distributions. If the Company at any time while this Warrant is
outstanding and unexpired shall pay a dividend or make any other distribution with respect to all of its outstanding common stock (except any distribution specifically provided for in the foregoing subsections 6(a) or 6(b)), then the Exercise Price
shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a
fraction (1) the numerator of which shall be the total number of shares of common stock outstanding immediately prior to such dividend or distribution (assuming the conversion, exchange or exercise of all securities which are convertible,
exchangeable or exercisable into common stock (hereinafter referred to as “on a fully diluted basis”)), and (2) the denominator of which shall be the total number of shares of common stock outstanding immediately after such dividend or
distribution on a fully diluted basis. 
  
 (d) Certificate as
to Adjustment. In each case of any adjustment in either the Exercise Price or in the number of shares of common stock, or other stock, securities or property receivable on the exercise of this Warrant, the Company shall compute such adjustment
in accordance with the terms of this Warrant and prepare a certificate signed by its Chief Executive Officer, Chief Financial Officer or other designated officer setting forth such adjustment and showing in reasonable detail the facts upon which
such adjustment is based, including a statement of the adjusted Exercise Price. The Company will cause copies of such certificate to be mailed to the registered holder. 
  
 7. Notices of Record Date. In the event of any taking by the Company of a record of its stockholders for the purpose
of determining stockholders who are entitled to receive payment of any dividend or other distribution, any right to subscribe for, purchase or otherwise acquire any share of any class or any other securities or property, or to receive any other
right, or for the purpose of determining stockholders who are entitled to vote in connection with any proposed merger or consolidation of the Company with or into any other corporation, or any proposed sale, lease or conveyance of all or
substantially all of the assets of the Company, or any proposed liquidation, dissolution or winding up of the Company, then, in connection with each such event, the Company shall mail to Holder at least ten (10) days prior written notice of the date
on which any such record is to be taken for the purpose of such dividend, distribution, right(s) or vote of the stockholders. Each such written notice shall specify the amount and character of any such dividend, distribution or right(s), and shall
set forth, in reasonable detail, the matter requiting any such vote of the stockholders. 
  
 8. Fractional Shares. No fractional shares of common stock will be issued in connection with any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based
upon the fair market value of the common stock (determined pursuant to Section 3(c)). 
  

 -4- 

 9. Compliance with Securities Act; Disposition of Warrant or Shares of Common Stock. 

 
 (a) Compliance with Securities Act. Holder, by acceptance hereof,
represents, warrants and agrees as follows as of the date hereof: 
  
 (i) this Warrant and the Shares to be issued upon exercise of this Warrant are being acquired for investment and not with a view to, or for resale in connection with, the distribution thereof; 
  
 (ii) Holder is an “accredited investor” within the
meaning of Rule 501 under the Securities Act of 1933, as amended (the “Securities Act”), has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of an investment in
the Company and is able to bear the economic risk of such investment; 
  
 (iii) this Warrant and the Shares to be issued upon exercise of this Warrant have not been and will not be registered or qualified under the Securities Act or any state securities laws and are offered in reliance upon
an exemption from registration under the Securities Act and similar state law exemptions, and this Warrant and the Shares to be issued upon exercise of this Warrant cannot be sold or otherwise disposed of by the holder thereof unless they are
subsequently registered under the Securities Act and similar state laws or sold or otherwise disposed of pursuant to an exemption therefrom; 
  
 (iv) there has been made available to Holder and its advisors the opportunity to ask questions of, and receive answers from, the Company
concerning the terms and conditions of the investment in this Warrant and the Shares to be issued upon exercise of this Warrant, and to obtain the Company’s reports and definitive proxy statements on Forms 10-K, 10-Q and 8-K, and Schedule 14-A
(collectively, the “‘34 Act Documents”) filed with the Securities and Exchange Commission (the “SEC”), and any additional information, to the extent that the Company possesses such information, or can acquire
it without unreasonable effort or expense, necessary to verify the accuracy of the information given to it, or to otherwise make an informed investment decision, and that Holder has had an opportunity to consult with counsel and other advisers about
the investment in this Warrant and the Shares issuable upon exercise of this Warrant, and that all material documents, records and books pertaining to such investment have, on request, been made available to Holder and its advisors. Holder has
reviewed the Company’s ‘34 Act Documents, referenced above, including any business plans or strategies of the Company set forth therein; 
  
 (v) this Warrant and all Shares to be issued upon exercise of this Warrant (unless registered under the Securities Act and similar state
laws) shall be stamped or imprinted with a legend in substantially the following form: 
  

 -5- 

 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933
AS AMENDED OR ANY APPLICABLE STATE SECURITIES LAWS AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR QUALIFICATION RELATED THERERTO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION OR QUALIFICATION IS NOT REQUIRED. 
  
 (vi) for securities laws purposes, the Holder’s address
is as indicated on the signature page hereto. 
  
 (b)
Disposition of Warrant and Shares. Prior and as a condition to any offer, sale or other disposition of this Warrant or any Shares acquired pursuant to the exercise of this Warrant, Holder and each subsequent holder of this Warrant shall
furnish to the Company such certificates, representations, agreements and other information, including an opinion of counsel, as the Company or the Company’s transfer agent reasonably may require to confirm that such offer, sale, other
disposition or exercise is being made pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Each certificate representing this Warrant or the Shares thus transferred (other than
pursuant to a registration statement that has been declared effective under the Securities Act and that remains effective and available for use at the time of such offer, sale, other disposition or exercise or a transfer pursuant to Rule 144) shall
bear a legend as to the applicable restrictions on transferability in order to insure compliance with the Securities Act unless, in the opinion of counsel reasonably acceptable to the Company and the Company’s transfer agent, such legend is not
required in order to insure compliance with the Securities Act. The Company may issue stop transfer instructions to its transfer agent in connection with the foregoing restrictions. 
  
 10. No Rights as Stockholders. No holder of this Warrant, as such, shall be entitled to the rights of a stockholder
or to vote upon any matter submitted to stockholders at any meeting thereof, or to receive notice of meetings, or be deemed the holder of common stock, unless and until this Warrant shall have been exercised and the Shares purchasable upon such
exercise shall have become deliverable, as provided herein. 
  
 11. Exchange and Registry of Warrant. This Warrant is exchangeable, upon the surrender hereof by the registered holder at the above-mentioned office or agency of the Company, for a new Warrant of like tenor and dated as of such
exchange. The Company shall maintain at the above-mentioned office or agency a registry showing the name and address of the registered holder. This Warrant may be surrendered for 
  

 -6- 

 exchange, transfer or exercise, in accordance with its terms, at such office or agency of the Company, and the Company
shall be entitled to rely in all respects, prior to written notice to the contrary, upon such registry. 
  
 12. Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a legal holiday. 
  
 13. Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated
only by an instrument in writing signed by the party against which enforcement of the same is sought. 
  
 14. Notices. All notices, requests, demands and other communications under this Warrant or in connection herewith shall be given to or made upon
(i) Holder at the address as indicated on the signature page hereto and (ii) the Company at CV Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA 94304, attention: General Counsel; with copies to Latham & Watkins LLP, 135 Commonwealth Drive,
Menlo Park, California 94025, attention: Alan C. Mendelson, Esq. All notices, requests, demands and other communications given or made in accordance with the provisions of this Warrant shall be in writing and shall be deemed received by a party upon
the earlier of actual receipt or, if sent by certified mail (postage pre-paid), five (5) days after deposit in the U.S. mail. Any party may, by written notice to the other, alter its address or respondent. 
  
 15. Binding Effect on Successors. This Warrant shall be binding upon
any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets. All of the covenants and agreements of between the parties shall inure to the benefit of the successors and
assigns of each party. 
  
 16. Lost Warrant or Stock
Certificates. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft destruction, or mutilation of this Warrant or any stock certificate issued upon exercise thereof and, in the ease of any such loss, theft or
destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the ease of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company shall make and deliver a new Warrant or stock
certificate of like tenor in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 
  
 17. No Impairment. The Company will not, by amendment of its Certificate of Incorporation or through any reorganization, recapitalization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all
times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder of this Warrant against impairment, including
without limitation with respect to Section 6 hereof. In case any event shall occur as to which the other provisions of Section 6 are not 
  

 -7- 

 strictly applicable but as to which the failure to make any adjustment would not fairly protect the purchase rights
represented by this Warrant in accordance with the essential intent and principles hereof, then, in each such case, the Board of Directors of the Company shall in good faith determine the adjustment, if any, on a basis consistent with the purchase
rights represented by this Warrant. Upon such determination, the Company will promptly deliver a copy thereof to the Holder and shall make the adjustments described therein. 
  
 18. Descriptive Heading. The descriptive headings of the several paragraphs of this Warrant are inserted for
convenience only and do not constitute a part of this Warrant. 
  
 19. Governing Law. This Warrant shall be construed and enforced in accordance with, and governed by, the internal laws of the State of Delaware, excluding the body of law applicable to conflicts of laws. 
  
 20. Assignment. Subject to compliance with applicable federal and
state securities laws and Section 9(b) hereof, this Warrant may be assigned by Holder in whole or in part. Upon delivery of a duly executed Assignment Form in the form attached hereto as Exhibit A-2, the Company shall record such assignment on its
books and all references to Holder hereunder shall be references to such registered holder. 
  
 21. Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the SEC that may permit the sale of securities to the public without registration, the Company agrees to
use its best efforts to make and keep public information regarding the Company available as those terms are understood and defined in Rule 144 under the Securities Act and file with the SEC in a timely manner all reports and other documents required
by the Company under the Securities Act and the Securities Exchange Act of 1934, and, so long as the Holder owns this Warrant or the Shares, furnish to the Holder upon written request a statement as to the Company’s compliance with the
reporting requirements of Rule 144 and of the Securities Act of 1933 and the Securities Exchange Act of 1934. 
  
 (Signature Page Follows) 
  

 -8- 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by a duly authorized officer.

  

	 CV THERAPEUTICS, INC.
 a Delaware corporation

		
	 By:
	 	 /s/    Louis G. Lange

	 	 	 Name: Louis G. Lange, M.D., Ph.D.
 Title: Chief Executive Officer

  
 ACKNOWLEDGED AND AGREED:

 QFinance, Inc. 
  

		
	 By:
	 	 /s/    Tom Perkins
        

	 	 	 Name: Tom Perkins
 Title: President

  
 Address:            QFinance, Inc. 
 4709 Creekstone
Drive 
 Suite 200, Riverbirch Building 
 Durham, North Carolina 27703 
 Attention: Thomas C. Perkins 
 Fax: (919) 998-2090 
  
 with a copy to:   Smith, Anderson, Blount,
Dorsett, 
 Mitchell & Jernigan, L.L.P. 
 2500 Wachovia Capitol Center 
 Raleigh, North Carolina 27601 
 Attention: Christopher B. Capel 
 Fax: (919) 821-6800 
  

 -9- 

 EXHIBIT A-1 
  
 NOTICE OF EXERCISE 
  
 NOTE: Prior and as a condition to any exercise of the Warrant, Holder and each subsequent holder of this Warrant shall furnish to the Company such certificates,
representations, agreements and other information, including an opinion of counsel, as the Company or the Company’s transfer agent reasonably may require to confirm that such exercise is being made pursuant to an exemption from, or in a
transaction not subject to, the registration requirements of the Securities Act of 1933, as amended. 
  
 To:
                                        
                                        
                                        
                                        
                                        
                   
  
 (Company Name) 
  
 1.      The undersigned hereby: 
  
 [_] elects to purchase shares of common stock of the 
 Company pursuant to the terms of the attached Warrant, and 
 tenders herewith payment of the purchase price of such shares in 
 full; or 
  
 [_] elects to exercise its net issuance rights pursuant to Section 
 3(b) of the attached Warrant with respect to shares of common stock. 
  
 2.      Please issue a certificate or certificates representing said shares in
the name of the undersigned or in such other name 
 or names as are specified below: 
  
                                       
                                        
                                        
                                        
                                        
    
  
 (Name) 
  
                                       
                                        
                                        
                                        
                                        
    
  
 (Address) 
  
                                       
                                        
                                        
                                        
                                        
    
  
 (Address) 
  
 By:
                                        
                                        
                                        
                                        
                                        
                   
  
 Date:
                                        
                                        
                                        
                                        
                                        
                
  
                                       
                                        
                                        
                                        
                                        
                             
 (Signature) 
  

 EXHIBIT A-2 
  
 ASSIGNMENT FORM 
  
 (To assign the foregoing Warrant, execute this form and supply the required information. Do not use this form to purchase shares.) 
  
 NOTE: Prior and as a condition to any offer, sale or other disposition of the Warrant or any
Shares acquired pursuant to the exercise of the Warrant, Holder and each subsequent holder of this Warrant shall furnish to the Company such certificates, representations, agreements and other information, including an opinion of counsel, as the
Company or the Company’s transfer agent reasonably may require to confirm that such offer, sale, other disposition or exercise is being made pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the
Securities Act of 1933, as amended. 
  
 FOR VALUE RECEIVED, the
foregoing Warrant and all rights evidenced thereby are hereby assigned to 
  
                                       
                                        
                                        
                                        
                                        
                                     
 (Please Print) 
  
 whose address is                                  
                                        
                                        
                                        
                                        
         
                               (Please Print) 
  
 Dated:                                     
                                        
                                        
                                        
                                        
      
  
 Holder’s Signature:                                 
                                        
                                        
                                        
                          
  
 Holder’s Address:                                  
                                        
                                        
                                        
                           
  
 Guaranteed Signature:                                  
                                        
                                        
                                        
                    
  
 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or
enlargement or any change whatever, and must be guaranteed by an eligible guarantor institution such as a bank, stockbroker, savings and loan association or credit union with membership in an approved medallion signature guarantee program. Officers
of corporations and those acting in 
  

 2 

 a fiduciary or other representative capacity should file proper evidence of authority to assign the
foregoing Warrant. 
  
 By:
                                        
                                        
                                        
                                        
                                        
                    
  
 Date:
                                        
                                        
                                        
                                        
                                        
                 
  
                                       
                                        
                                        
                                        
                                        
                              
 (Signature) 
  

 3Amended and Restated Sales and Marketing Services Agreement

 Exhibit 10.1 
  
 AMENDED AND RESTATED 
 SALES AND MARKETING SERVICES AGREEMENT 
  
 This Amended and Restated Sales and Marketing Services Agreement(the “Agreement”) is entered into as of July 9, 2003 (the “Effective Date”) by and between CV
Therapeutics, Inc.,a Delaware corporation (“CVT”), Innovex (North America) Inc., a New Jersey corporation, as successor to Innovex Inc., a Delaware corporation (“Innovex Inc.”), Innovex LP, a New Jersey
limited partnership (“Innovex”) and Quintiles Transnational Corp., a North Carolina corporation (“Quintiles”), each on behalf of itself and its Affiliates (as defined below). CVT, Innovex Inc., Innovex and Quintiles
are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
  
 RECITALS 
  
 WHEREAS, CVT, Innovex Inc. and Quintiles (for purposes of Article 8 thereof) are parties to that certain Sales and Marketing Services Agreement, dated as
of May 5, 1999 (the “Services Agreement”), relating to the sale and marketing of the Product (as defined below); 
  
 WHEREAS, CVT and Quintiles are parties to that certain Loan Agreement, dated as of May 5, 1999 (the “Loan Agreement”) and that certain
Security Agreement, dated as of May 5, 1999 (the “Security Agreement”), and together with Fort Know Escrow Services as the Escrow Agent, are parties to that certain Escrow Agreement, dated as of May 5, 1999 (the “Escrow
Agreement,” and together with the Loan Agreement and the Security Agreement, the “Ancillary Agreements”); 
  
 WHEREAS, in connection with the Loan Agreement, CVT has delivered to Quintiles executed copies of that certain promissory note dated May 5, 1999 in an
aggregate principal amount of $10,000,000 and that certain promissory note dated May 5, 1999 in an aggregate principal amount of all advances made by Quintiles to CVT under the Loan Agreement (collectively, the “Notes”); 

 
 WHEREAS, Innovex Inc. has transferred all of its rights and
responsibilities under the Services Agreement to Innovex, a wholly-owned subsidiary of Quintiles and Affiliate of Innovex Inc.; 
  
 WHEREAS, the Parties desire to terminate the Ancillary Agreements and the Notes and to terminate each Party’s rights and responsibilities under such
Ancillary Agreements and Notes (except as specifically set forth in this Agreement); 
  
 WHEREAS, it is the intent of the Parties that this Agreement amend and restate in its entirety the Services Agreement and that, from and after the Effective Date, the Services Agreement shall be of no further force
and effect whatsoever; and 
  
 WHEREAS, this Agreement is made in
renewal, amendment, restatement, modification and novation of the obligations under the Services Agreement. 

 AGREEMENT 
  
 NOW, THEREFORE, in consideration of the foregoing recitals, the Parties hereto agree as follows: 
  
 1. Definitions. 
  
 1.1 “Affiliate” means any corporation or business entity
controlled by, controlling, or under common control with a Party to this Agreement. For this purpose, “control” shall mean direct or indirect beneficial ownership of at least fifty percent (50%) of the voting stock or income interest in
such corporation or other business entity, or such other relationship as, in fact, constitutes actual control. 
  
 1.2 “Approval” means the first approval during the Term of this Agreement by the FDA authorizing CVT to market the Product in the United
States. 
  
 1.3 “Approval Date” means the date
upon which CVT is informed in writing by the FDA of the Approval. 
  
 1.4 “FDA” means the U.S. Food and Drug Administration. 
  
 1.5 “Product” means ranolazine (the pharmaceutical agent described in U.S. Patent No. 4,567,264) in a sustained release formulation which is the subject of a new drug application filed by CVT with the
FDA, or any other formulation and/or indication for ranolazine (the pharmaceutical agent described in U.S. Patent No. 4,567,264). 
  
 1.6 “Quintiles Services” means (a) any service offered by Innovex, (b) any other commercialization service offered by Quintiles or its
Affiliates, or (c) any post-approval clinical service offered by Quintiles or its Affiliates. 
  
 1.7 “Third Party” means any entity or person other than a Party or an Affiliate of any of them. 
  
 2. Termination of Ancillary Agreements and Replacement of Services Agreement by This Agreement. 
  
 2.1 Confirmation of No Breach or Default. Effective as of the
Effective Date, the Parties hereby confirm that they have no losses, claims, damages, liabilities, costs or expenses relating to or arising from any default or breach by the other Party of any representation, warranty, covenant, term or other
provision of any of the Ancillary Agreements, the Notes or the Services Agreement. 
  
 2.2 Termination of Ancillary Agreements and the Notes. Effective as of the Effective Date, each of the Ancillary Agreements and the Notes are hereby expressly terminated, cancelled and superseded in their
entirety by this Agreement and shall have no further force and effect; and, notwithstanding anything in such Ancillary Agreements or Notes to the contrary, the Parties shall have no further rights or obligations under such Ancillary Agreements or
Notes. 
  

 -2- 

 2.3 Replacement of Services Agreement by This Agreement. Effective as of the Effective Date, this
Agreement hereby amends, restates and replaces in its entirety the Services Agreement and the Parties’ respective rights and obligations thereunder, such that from and after the Effective Date the Services Agreement is of no further force and
effect whatsoever. Without limiting the generality of the foregoing, the Parties acknowledge and agree that all of the provisions of the Services Agreement listed in Section 14.10 of the Services Agreement, which were provided therein as surviving
expiration or termination of the Services Agreement, are as of the Effective Date of no further force and effect whatsoever. 
  
 2.4 Release of Security Interests; Filings; Cooperation. Effective as of the Effective Date, Quintiles hereby acknowledges and agrees that there
are no outstanding obligations of CVT under the Notes and that no Pre-Approval Advances or any other Advances (each as defined in the Loan Agreement) were made to CVT at any time, and Quintiles hereby unconditionally and irrevocably releases all
security interests or other claims or rights (the “Security Interests”) granted or purported to be granted pursuant to the Security Agreement (the “Release”). Quintiles hereby agrees to promptly (but in any event no
later than ten (10) business days following the Effective Date) make all filings required to evidence the Release, including, but not limited to, any and all UCC (as defined in the Security Agreement) filings, and all filings, if any, with the
United States Patent and Trademark Office. Quintiles shall promptly execute and deliver any further instrument, document or notice as may be necessary, desirable or which CVT may reasonably require in order to evidence the termination and Release of
the Security Interests. 
  
 2.5 Return of the Notes Marked
Cancelled. Quintiles shall return each of the Notes to CVT (attn: General Counsel) marked “Cancelled” within ten (10) business days after the Effective Date. Notwithstanding any failure of Quintiles to return and/or mark a Note, the
Notes will be automatically cancelled at the Effective Date. 
  
 2.6 Return of Escrow Property. In connection with the termination of the Escrow Agreement, the Parties acknowledge and agree that the Escrow Property (as defined in the Escrow Agreement) shall be returned as follows. Notwithstanding
the Claims Deadline under Section 2.4 of the Escrow Agreement, Quintiles and CVT each hereby acknowledge and agree that Quintiles shall be entitled to receive the Borrower NDA Letter (a copy of which is attached as an exhibit to the Escrow
Agreement) from the Escrow Agent (as defined in the Escrow Agreement), and CVT shall be entitled to receive the Lender NDA Letter (a copy of which is attached as an exhibit to the Escrow Agreement) from the Escrow Agent. To effectuate the foregoing,
within ten (10) business days following the Effective Date the Parties agree to send to the Escrow Agent the joint instruction letter set forth in Exhibit A attached hereto and incorporated herein by this reference, instructing the Escrow
Agent in connection with the mutually agreed-upon termination of the Escrow Agreement to deliver and return said Borrower NDA Letter to Quintiles (attn: Thomas C. Perkins) and to deliver and return said Lender NDA Letter to CVT (attn: Tricia Borga
Suvari, General Counsel), in each case no later than ten (10) business days after the Effective Date. 
  

 -3- 

 3. Commercialization Relationship. 
  
 3.1 Purchase of Quintiles Services. The parties wish to establish the
arrangements set forth in this Section 3 under which CVT will engage Quintiles and its Affiliates to perform Quintiles Services and Quintiles and its Affiliates will provide Quintiles Services, and CVT and Quintiles agree to enter into certain
Commercialization Services Agreements referred to below. It is the intent of CVT and Quintiles that CVT will engage Quintiles and its Affiliates pursuant to one or more Commercialization Services Agreements to provide Quintiles Services having an
Aggregate Expected Value (as defined below) of Ten Million Dollars ($10,000,000.00) or more by or before the date that is six (6) months following the Approval Date (the “CSAs Deadline”). Each engagement for Quintiles Services will
be set forth in a definitive written agreement between CVT and Quintiles or its applicable Affiliate, containing appropriate terms and conditions as may be mutually and reasonably acceptable to the parties (each such agreement, a
“Commercialization Services Agreement” or “CSA”). Quintiles agrees that the prices to be paid by CVT for Quintiles Services pursuant to the Commercialization Services Agreements shall equal, as nearly as reasonably
practicable, the prices charged by Quintiles or its Affiliates to Third Party customers buying comparable services on comparable terms and conditions, such as comparable quantity and scope of services and comparable completion time frames. Upon such
time as CVT notifies Quintiles with respect to a particular engagement for Quintiles Services, CVT and Quintiles agree to work expeditiously and in good faith to enter into an applicable Commercialization Services Agreement. Each CSA shall include a
provision setting forth the expected value of the CSA (the expected value of all CSAs taken together shall be referred to herein as the “Aggregate Expected Value”). In the event that CVT or Quintiles believes that the expected value
as set forth in a CSA should be modified, such Party may contact the other Party, and the Parties agree to discuss in good faith such proposed modification. In the event that CVT and Quintiles initiate working toward a particular CSA but are unable
to reach a definitive agreement, such proposed CSA shall not in any manner affect the Aggregate Expected Value or other calculations under this Agreement. 
  
 3.2 Payment by CVT. In the event that by the CSAs Deadline set forth above the Aggregate Expected Value of the CSAs does not equal or exceed Ten
Million Dollars ($10,000,000.00), CVT shall be obligated to pay Quintiles a lump-sum cash payment equal to Ten Percent (10%) of the difference between Ten Million Dollars ($10,000,000.00) and the Aggregate Expected Value of the CSAs that have been
executed by CVT and Quintiles by the CSAs Deadline. Any and all CSAs entered into by the Parties under Section 3.1 above, together with the cash payment (if any is owed hereunder) under the immediately preceding sentence of this Section 3.2, shall
be in full satisfaction of all of the Parties’ respective rights and obligations to each other under this Article 3, including in the event that the Aggregate Expected Value of the CSAs by the CSAs Deadline does not equal or exceed Ten Million
Dollars ($10,000,000.00). The cash payment (if any is owed hereunder) shall be paid by CVT to Quintiles no later than thirty (30) days after the CSAs Deadline. 
  

3.3 Miscellaneous. The foregoing provisions of Sections 3.1 and 3.2 shall not apply, shall have no force or effect, and shall not create any
rights or obligations in the Parties if (a) the Product does not receive Approval during the Term of this Agreement (as defined below), or (b) CVT does not continue to hold rights covering the Product on the CSAs Deadline (through ownership, license
or other rights). 
  

 -4- 

 4. Preferred Provider Relationship. The Parties wish to preserve, foster and further
develop the working relationship and communications established by the Parties under the Services Agreement. Accordingly, CVT designates Quintiles (which for purposes of this Section 4 shall include its Affiliates) as a “preferred
provider,” such that during the Term of this Agreement CVT will give Quintiles the opportunity to bid on future development and commercialization projects involving services which (a) Quintiles has demonstrated expertise, quality and
competitive pricing, (b) CVT (which for purposes of this Section 4 shall include its Affiliates) has elected to outsource or otherwise engage a Third Party to perform, and (c) are expected by CVT to involve payments individually or in the aggregate
of Three Hundred Thousand Dollars ($300,000.00) or more. The Parties agree that for purposes of the foregoing clause (a), the Parties initially shall refer to the lists of services described in the “Business” Section, “Product
Development Offerings” and Commercial Services Offerings” of the Annual Report on Form 10-K (as amended) filed by Quintiles with the Securities Exchange Commission for the year ended December 31, 2002. Quintiles shall use its Alliance
Manager under Section 5 below to keep CVT apprised of additional services that may meet the standard under the foregoing clause (a). CVT shall provide Quintiles with the opportunity to bid on at least twelve (12) such projects during the Term;
provided, however, that if CVT does not provide Quintiles with the opportunity to bid on at least twelve (12) such projects during the Term, the respective rights and obligations of the Parties under Sections 4 and 5 of this Agreement shall
automatically be extended for an additional period of one (1) year. Quintiles agrees that the prices for such services shall equal, as nearly as reasonably practicable, the prices charged by Quintiles to Third Party customers buying comparable
services on comparable terms and conditions, such as comparable quantity and scope of services and comparable completion time frames. The Parties agree to communicate, collaborate and otherwise endeavor in good faith to fulfill the intent of this
Section 4. 
  
 5. Alliance Managers. For purposes of
this Agreement, Quintiles and CVT will each appoint and maintain an operational Alliance Manager. The Alliance Managers shall oversee potential and awarded CSAs under Section 3 above and on-going clinical projects. Additionally, the Alliance
Managers shall coordinate preferred provider arrangements, including the Quintiles services and opportunities to bid on CVT projects under Section 4 above. Further, the Alliance Managers shall generally serve to coordinate and facilitate the other
activities of the Parties under this Agreement. The Quintiles Alliance Manager shall report monthly to Dennis Gillings at Quintiles. For purposes of such CSAs, projects and arrangements, the PharmaBio Development organization within Quintiles will
interact directly with the Quintiles clinical development team and Innovex to ensure that pricing and operational delivery meet CVT’s requirements. 
  
 6. Common Stock Warrant. Upon the execution and delivery of this Agreement by each of the Parties, CVT shall issue to Quintiles or its
designee a warrant, in the form attached hereto and incorporated herein by reference as Exhibit B, to purchase two hundred thousand (200,000) shares of common stock of CVT (the “Warrant”). 
  
 7. Representations and Warranties. Each Party represents and
warrants to the other that as of the Effective Date: 
  

 -5- 

 7.1 Corporate Power. It is duly organized and validly existing under the laws of its state or
country of incorporation, and has full corporate power and authority to enter into this Agreement and the Warrant and to carry out the provisions hereof and thereof. 
  
 7.2 Due Authorization. It is duly authorized to execute and deliver this Agreement and the Warrant, and to perform
its obligations hereunder and thereunder, and the person or persons executing this Agreement or the Warrant on its behalf has been duly authorized to do so by all requisite corporate action. 
  
 7.3 Binding Agreement. This Agreement and the Warrant are legally
binding upon it and enforceable against it in accordance with their respective terms. The execution, delivery and performance of this Agreement and the Warrant by it do not conflict with any agreement, instrument or understanding, oral or written,
to which it is a Party or by which it may be bound, nor violate any material law, regulation or order of any court, governmental body or administrative or other agency having jurisdiction over it. 
  
 7.4 Validity. It is aware of no action, suit or inquiry or
investigation instituted by any governmental agency that questions or threatens the validity of this Agreement or the Warrant, or the consummation of the transactions contemplated hereby or thereby. 
  
 8. Confidentiality. 
  
 8.1 Confidential Information. Each Party agrees that information
specifically relating to the marketing and sales of the Product, or the business affairs or finances of the other Parties or such other Party’s Affiliates or suppliers, agents, distributors, licensees or customers, which is or has been
disclosed in writing and marked “confidential”, or disclosed orally or in any other tangible form and reduced to a written summary marked “confidential”, and which in any case came into possession of such Party under the Services
Agreement or comes into the possession of such Party under this Agreement, shall be considered confidential information (“Confidential Information”). Each Party agrees for a period of five (5) years from the Effective Date to hold
Confidential Information in strict confidence and disclose it only on a need-to-know basis to Affiliates, subcontractors and employees who are under a written obligation to maintain the confidentiality of the information. The foregoing obligations
of confidentiality and limited use shall not apply to information: 
  
 8.1.1 which can be shown by written documentation to have been known by the recipient Party prior to its receipt from the other Party; 
  
 8.1.2 which is public or lawfully becomes generally available to the public through no fault of the
recipient Party; 
  
 8.1.3 which is lawfully
acquired by the recipient Party from a Third Party without being made subject to an obligation of confidence by the Third Party; 
  
 8.1.4 which by mutual written agreement of the Parties is released from a confidential status; or 
  

 -6- 

 8.1.5 which is required by the recipient Party to be disclosed under any statutory,
regulatory or judicial requirement, including but not limited to any filing with the Securities Exchange Commission; provided, however, that in any such event, the recipient Party shall preserve and protect the confidentiality of the
other Party’s Confidential Information to the extent possible, and will notify the other Party prior to any such disclosure. 
  
 8.2 Ownership of Data; No License. It is expressly acknowledged and agreed that no Party transfers or transferred to any other Party by operation
of this Agreement, the Services Agreement or any Ancillary Agreement any patent right, copyright or other proprietary right. All data and information generated or derived by Quintiles, Innovex Inc. and/or Innovex as the result of services performed
by Quintiles, Innovex Inc. and/or Innovex under the Services Agreement or this Agreement shall be and remain the exclusive property of CVT. Any inventions that may evolve from the data and information as the result of services performed by
Quintiles, Innovex Inc. and/or Innovex under the Services Agreement or this Agreement shall belong to CVT, and each of Quintiles, Innovex Inc. and Innovex agree to assign its respective rights in all such inventions and/or related patents (if any)
to CVT. Notwithstanding the foregoing, CVT acknowledges that Quintiles, Innovex Inc. and Innovex possess certain inventions, processes, know-how, trade secrets, improvements, other intellectual properties and other assets, including but not limited
to analytical methods, procedures and techniques, procedure manuals, personnel data, financial information, computer technical expertise and software, which have been independently developed by Quintiles, Innovex Inc. and/or Innovex and which relate
to their respective business or operations (collectively, “Quintiles Property”). The Parties agree that any Quintiles Property or improvement thereto which is used, improved, modified or developed by Quintiles, Innovex Inc. and/or
Innovex under or during the term of the Services Agreement or this Agreement is and shall remain the sole and exclusive property of Quintiles, Innovex Inc. or Innovex, as applicable. 
  
 8.3 Firewall. In connection with information exchanged under this Agreement and/or with the provision of any
Quintiles Services under any CSA, Quintiles (for purposes of this Agreement) and Innovex or any Quintiles Affiliate (for purposes of any CSA to which it is a party) shall keep separate and shall not share with other parts of its organization that
are or may be performing services for a competing product, the material and information supplied and/or generated hereunder or thereunder. 
  
 9. Indemnification. 
  
 9.1 Indemnification by CVT. CVT shall indemnify, defend, save, protect, and hold harmless Quintiles, its Affiliates, and its and their respective
directors, officers, employees, and agents (“Quintiles Indemnitees”) against any and all losses, claims, damages, liabilities, costs and expenses (including reasonable attorneys fees and expenses and court costs) (collectively,
“Losses”) resulting or arising from any Third Party claims, actions, proceedings, investigations or litigation relating to or arising from or in connection with: (a) the breach by CVT of any of its obligations under the Services
Agreement prior to the Effective Date or under this Agreement or (b) the design, development, manufacture, sale, distribution or use of the Product. Notwithstanding the foregoing, (i) nothing contained in these indemnification obligations shall
override any indemnification obligations agreed to by the Parties in any 
  

 -7- 

 Commercial Services Agreement under Section 3 above or any agreement for services awarded to Quintiles under Section 4
above, and (ii) CVT shall not be required to indemnify Quintiles or any of the Quintiles Indemnitees for any Losses to the extent they arise from the negligent or wrongful acts or omissions of Quintiles or any of the Quintiles Indemnitees or any
breach by Quintiles or any of the Quintiles Indemnitees of its obligations under the Services Agreement prior to the Effective Date or under this Agreement. 
  
 9.2 Indemnification by Innovex. Quintiles, Innovex and Innovex Inc., jointly and severally, shall indemnify, defend, save, protect, and hold
harmless CVT, its Affiliates, and its and their respective directors, officers, employees, and agents (the “CVT Indemnitees”) against any and all Losses resulting or arising from any Third Party claims, actions, proceedings,
investigations or litigation relating to or arising from or in connection with the breach by Quintiles, Innovex or Innovex Inc. of any of its respective obligations under the Services Agreement prior to the Effective Date or under this Agreement.
Notwithstanding the foregoing, none of Quintiles, Innovex or Innovex Inc. shall be required to indemnify CVT or any of the CVT Indemnitees for any Losses to the extent they arise from the negligent or wrongful acts or omissions of CVT or any of the
CVT Indemnitees or the breach by CVT or any of the CVT Indemnitees of its obligations under the Services Agreement prior to the Effective Date or under this Agreement. 
  
 9.3 Procedure. The Party seeking indemnification hereunder (the “Indemnified Party”) shall (a)
promptly notify the Party obligated to indemnify (the “Indemnifying Party”) of any Losses for which the Indemnified Party seeks indemnification; (b) cooperate fully with Indemnifying Party and its legal representatives in the
investigation of any matter the subject of indemnification; (c) permit the Indemnifying Party full control over the defense and settlement of any matter the subject of indemnification; and (d) not unreasonably withhold its approval of the settlement
of any claim, liability or action by Indemnifying Party covered by this indemnification provision. 
  
 9.4 No Consequential Damages. Notwithstanding the Parties’ rights and remedies in equity and except with respect to indemnification
obligations under Sections 9.1 and 9.2, no Party, nor its Affiliates or their respective directors, officers, employees or agents shall have any liability to any other for any special, incidental, indirect or consequential damages, including, but
not limited to the loss of opportunity, use, revenue or profit, in connection with or arising out of this Agreement even if such damages were foreseeable. 
  
 10. Dispute Resolution. 
  
 10.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the term of this Agreement which
relate to such Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and
without resort to litigation, as such may be accomplished by good faith negotiations between the Parties, within thirty (30) days of notice. If such dispute remains unresolved at that point, it shall promptly be submitted to the Chief Executive
Officer of Quintiles and the Chief Executive Officer of CVT who will meet in person or by teleconference 
  

 -8- 

 at least once within thirty (30) days after such submission and attempt to resolve the matter or matters in dispute.

  
 10.2 Governing Law. Resolution of all disputes
arising out of or related to this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of Delaware, as
applied to agreements executed and performed entirely in the State of Delaware by residents of the State of Delaware, without regard to conflicts of law rules. 
  

11. Term and Termination. 
  
 11.1 Term. The term of this Agreement (“Term”)will begin on the Effective Date and continue until the third (3rd) anniversary of the Effective Date, unless the Agreement is terminated earlier in accordance with this Section 11; provided,
however, if the Product receives Approval prior to the third (3rd) anniversary of the Effective Date, but after
thirty (30) months following the Effective Date, then the Term of this Agreement shall be extended until the date which is six (6) months following the date of such Approval. 
  
 11.2 Material Breach. CVT may terminate this Agreement by written notice at any time if Quintiles, Innovex
Inc. or Innovex defaults in the performance of any material obligations under this Agreement. Quintiles, Innovex Inc. and Innovex may terminate this Agreement by written notice at any time if CVT defaults in the performance of any material
obligations under this Agreement. In the event of such default, the Party declaring the default shall provide the defaulting Party or Parties with written notice setting forth the nature of the default, and the defaulting Party or Parties shall have
thirty (30) days to cure the default. If the defaulting Party or Parties fail(s) to cure the default within the foregoing time period, and provided the default is continuing, the other Party or Parties, as the case may be, may terminate this
Agreement by written notice to the defaulting Party or Parties, which notice shall be effective upon receipt. 
  
 11.3 Bankruptcy. CVT may terminate this Agreement by written notice to Quintiles, Innovex Inc. or Innovex, if Quintiles, Innovex Inc. or Innovex
files a petition for bankruptcy, reorganization or arrangement under any state statute, or makes an assignment for the benefit of creditors or takes advantage of any insolvency statute or similar statute, or such filing is made by a Third Party, and
such filing is not withdrawn within sixty (60) days of the filing date, or if a receiver or trustee is appointed for the property and assets of Quintiles, Innovex Inc. or Innovex and the receivership proceedings are not dismissed within sixty (60)
days of such appointment. Quintiles, Innovex Inc. and Innovex may terminate this Agreement by written notice to CVT if CVT files a petition for bankruptcy, reorganization or arrangement under any state statute, or makes an assignment for the benefit
of creditors or takes advantage of any insolvency statute or similar statute, or such filing is made by a Third Party, and such filing is not withdrawn within sixty (60) days of the filing date, or if a receiver or trustee is appointed for the
property and assets of CVT and the receivership proceedings are not dismissed within sixty (60) days of such appointment. 
  
 11.4 Accrued Rights. Termination of this Agreement for whatever reason shall not affect the accrued rights of any Party arising under or out of
this Agreement and all 
  

 -9- 

 provisions which expressly or by implication survive this Agreement shall remain in full force and effect. Termination of
this Agreement shall not relieve the Parties of any liability which accrued hereunder prior to the effective date of such termination nor preclude any Party from pursuing all rights and remedies it may have hereunder or at law or in equity with
respect to any breach of this Agreement nor prejudice any Party’s right to obtain performance of any obligation. 
  
 11.5 Survival. The following provisions of this Agreement shall survive any expiration or termination of this Agreement, and if time periods are
specified, for the period of time specified: Sections 8, 9, 11.5 and 12.4. The Warrant shall survive any expiration or termination of this Agreement, in accordance with its terms and conditions. 
  
 12. Miscellaneous. 
  
 12.1 Nonsolicitation of Employees. For a period of six (6) months
after the Effective Date, each Party agrees that neither it nor any of its divisions or operating groups that directly participated in or was directly responsible for the development or commercialization of the Product pursuant to the Services
Agreement shall, directly or indirectly, recruit, solicit or induce any employee of the other Party to terminate his or her employment with such other Party. 
  
 12.2 Publicity. The Parties agree that promptly following the execution of this Agreement, they will issue a joint press release in the form
attached hereto and incorporated herein by reference as Exhibit C (the “Joint Announcement”). Subsequent announcements related to this Agreement shall be by mutual consent; provided, however, that subsequent disclosures
(including but not limited to filings under the Securities and Exchange Act of 1934, as amended) by a Party that merely restate all or part of the text or substance of the Joint Announcement shall not require such mutual consent. The Parties
acknowledge and agree that, just as in the Services Agreement, CVT shall continue to be the Party responsible for disclosure of information related to the sales, performance, pharmaceutical characteristics and clinical study data of the Product, and
each of Quintiles, Innovex Inc. and Innovex agree not to make any disclosures, public or private, in that regard. Each Party is otherwise authorized to make any disclosures as may be required by law, including but not limited to disclosures as
required under the Securities and Exchange Act of 1934, as amended. 
  
 12.3 Entire Agreement; Amendment. This Agreement and the exhibits attached hereto (including the Warrant) set forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto, and supersede and terminate all prior agreements and understandings between the Parties (including the Services Agreement and the Ancillary Agreements). There are no covenants, promises,
agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 
  

 -10- 

 12.4 Notices. Any notice required or permitted to be given under this Agreement shall be in
writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes five (5) days after mailed by first class certified or registered mail, postage prepaid, the next business day after delivery by
overnight courier service, or the same business day as personally delivery or transmission by fax machine (with machine confirmation of complete delivery), in any case to the proper address of the Party. Unless otherwise specified in writing in
accordance with this Section 12.4, the addresses of the Parties for all notices under this Agreement shall be as described below: 
  

	 	For CVT:	 	CV THERAPEUTICS, Inc. 

 3172 Porter Drive

 Palo Alto, California 94304 
 Attention: Tricia Borga Suvari, General Counsel 
 Fax: (650) 858-0388 
  

	 	with a copy to:	 	Latham & Watkins LLP 

 135
Commonwealth Drive 
 Menlo Park, California 94025 
 Attention: Alan C. Mendelson, Esq. 
 Fax: (650) 463-2600 
  

	 	for Innovex:	 	Innovex LP 

 c/o Quintiles Transnational
Corp. 
 4709 Creekstone Drive 
 Suite 200, Riverbirch Building 
 Durham, North Carolina 27703 
 Attention: Thomas C. Perkins 
 Fax: (919) 998-2090 
  
 with a
copy as provided below; 
  

	 	for Innovex Inc.:	 	Innovex (North America) Inc. 

 c/o
Quintiles Transnational Corp. 
 4709 Creekstone Drive 
 Suite 200, Riverbirch Building 
 Durham, North Carolina 27703 
 Attention: Thomas C. Perkins 
 Fax: (919) 998-2090 
  
 with a copy as provided below; and 
  

	 	for Quintiles:	 	Quintiles Transnational Corp. 

 4709
Creekstone Drive 
 Suite 200, Riverbirch Building 
 Durham, North Carolina 27703 
 Attention: Thomas C. Perkins 
 Fax: (919) 998-2090 
  

 -11- 

 with, in the case of any notice to Innovex, Innovex Inc. or Quintiles hereunder, a copy to: 

 
 Smith, Anderson, Blount, Dorsett, 
 Mitchell & Jernigan, L.L.P. 
 2500 Wachovia Capitol Center 
 Raleigh, North Carolina 27601 
 Attention: Christopher B. Capel 
 Fax: (919) 821-6800 
  
 or to such other
destination as any Party may hereafter notify the other Party in accordance with this Section 12.4. 
  
 12.5 No Strict Construction. This Agreement has been prepared jointly and shall not be strictly construed against any Party. 
  
 12.6 Assignment. No Party may assign or transfer this Agreement or any
rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment without the other Party’s consent to Affiliates or to a successor to substantially all of the business of such
Party, whether in a merger, sale of stock, sale of assets or other transaction. Any permitted successor or assignee of rights and/or obligations hereunder shall, in a writing to the other Parties, expressly assume performance of such rights and/or
obligations. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 12.6 shall be null and void and of no legal effect. If
any Party assigns this Agreement to an Affiliate pursuant to this Section 12.6, the assigning Party shall provide a continuing guarantee of the performance of this Agreement by such Affiliate. 
  
 12.7 Performance by Affiliates. Obligations under this Agreement may
be performed by Affiliates of the Parties only with the prior consent of the other Parties. In the event any such performance is carried out by Affiliates with the prior consent of the other Parties, each Party guarantees performance of this
Agreement by its Affiliates. No Affiliate of a Party may make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way. 
  
 12.8 Counterparts. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
  
 12.9 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and
intent of this Agreement. 
  
 12.10 Severability. If any
one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve
to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to 
  

 -12- 

 replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by
the Parties when entering this Agreement may be realized. 
  
 12.11 Ambiguities. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 
  
 12.12 Headings. The headings for each section in this Agreement have
been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 
  
 12.13 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular
default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a
particular period of time. 
  
 (Signature Page Follows)

  
  

 -13- 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives as of the date first set forth above. 
  

	CV THERAPEUTICS, INC.
		
	 By:
	 	 /s/ Louis G. Lange

	 	 	 Louis G. Lange, M.D., Ph.D.
 Chief Executive Officer

	
	INNOVEX (NORTH AMERICA) INC.
		
	 By:
	 	 /s/ Beverly Rubin

	 	 	 Name: Beverly Rubin
 Title: Deputy General Counsel

	
	INNOVEX LP
		
	 By:
	 	 /s/ Beverly Rubin

	 	 	 Name: Beverly Rubin
 Title: Deputy General Counsel

	
	QUINTILES TRANSNATIONAL CORP.
		
	 By:
	 	 /s/ Tom Perkins

	 	 	 Name: Tom Perkins
 Title: SVP – Corporate Development

  
  

 -14- 

 EXHIBIT A 
  

FORM OF JOINT INSTRUCTION TO ESCROW AGENT 
  
 July     , 2003 
  
 Fort Know Escrow Services, Inc. 
 2100 Norcross Parkway, Suite 150 
 Norcross, Georgia 30071 
 Attention: Glen Bryman 
  

	 	Re:	 	Escrow Agreement dated May 5, 1999 

 CV
Therapeutics, Inc./Quintiles Transnational Corp. 
  
 Dear Mr. Bryman: 
  
 We make reference to that certain
Escrow Agreement (the “Escrow Agreement”), dated as of May 5, 1999, by and among Quintiles Transnational Corp., a North Carolina corporation (“Quintiles”), CV Therapeutics, Inc., a Delaware corporation
(“CVT”) and Fort Knox Escrow Services, Inc., a Georgia corporation (the “Escrow Agent”). Capitalized terms not defined in this letter shall have the meanings given to them in the Escrow Agreement. 
  
 Pursuant to the Escrow Agreement, Quintiles and CVT hereby jointly instruct
you (“Delivery Instruction”) as the Escrow Agent to promptly deliver (i) to Quintiles (attention: Thomas C. Perkins, with a copy to Quintiles’s outside counsel as provided below), the Borrower NDA Letter (a copy of which is
attached as an exhibit to the Escrow Agreement) and (ii) to CVT (attention: Tricia Borga Suvari, General Counsel, with a copy to CVT’s outside counsel as provided below), the Lender NDA Letter (a copy of which is attached as an exhibit to the
Escrow Agreement), with each such delivery to occur no later than ten (10) business days after the date set forth above. Quintiles and CVT each hereby (i) consent to and waive any objections to this Delivery Instruction and (ii) acknowledge and
agree that, after the delivery of the Escrow Property by the Escrow Agent pursuant to the foregoing Delivery Instruction, the Escrow Property will be completely distributed in accordance with the terms of the Escrow Agreement, and immediately
thereafter the Escrow Agreement shall be terminated pursuant to Section 4.9 of the Escrow Agreement. 
  
 Please note that the required copy to Quintiles’s outside counsel should be directed to Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan,
L.L.P., 2500 Wachovia Capitol Center, Raleigh, North Carolina 27601, Attention: Christopher B. Capel, Esq. 
  
 Please note that the required copy to CVT’s outside counsel should be directed to Latham & Watkins LLP, 135 Commonwealth Drive, Menlo Park,
California 94025, Attention: Alan C. Mendelson, Esq. 
  
 Should
you have any questions, please contact Tricia Borga Suvari of CVT at (650) 384-8611 or Thomas C. Perkins of Quintiles at (919) 998-2080. 

 Thank you. 
  

	CV THERAPEUTICS, INC.	 	 	 	QUINTILES TRANSNATIONAL CORP.
					
	By:	 	  

	 	 	 	By:	 	  

	 	 	 Louis G. Lange, M.D., Ph.D.
 Chief Executive Officer
	 	 	 	 	 	 Name:
 Title:

 EXHIBIT B 
  

FORM OF COMMON STOCK WARRANT 

 EXHIBIT C 
  

FORM OF PRESS RELEASE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00053-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00053-of-00352.parquet"}]]